CAS: 1655504-04-3

Orelabrutinib is a small-molecule Bruton’s tyrosine kinase (BTK) inhibitor, which is synthesized chemically. This selective inhibitor targets BTK, a key enzyme involved in the B-cell receptor signaling pathway. By binding covalently to cysteine-481 in BTK, orelabrutinib effectively blocks the downstream signaling, leading to apoptosis of malignant B-cells. Orelabrutinib is utilized primarily in the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Its high selectivity for BTK minimizes off-target effects, providing a more favorable safety profile compared to earlier generation BTK inhibitors. The compound's pharmacokinetic properties allow for potent and sustained inhibition of BTK, offering an effective therapeutic option for patients with these hematological cancers. Orelabrutinib's role in targeted cancer therapy exemplifies the ongoing advancements in precision medicine, offering hope for improved management of B-cell-derived malignancies.

Orelabrutinib

Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).

6-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)Nicotinamide